Xeris Biopharma Holdings (XERS) Gross Profit (2020 - 2026)

Xeris Biopharma Holdings has reported Gross Profit for 7 years, with the latest figure at $72.6 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 41.18% year-over-year to $72.6 million; the trailing twelve-month figure through Mar 2026 stood at $270.4 million (up 47.81% YoY), and the FY2025 full-year result was $249.3 million, up 49.95% from the prior year.
• Gross Profit for Q1 2026 stood at $72.6 million, down from $74.9 million in the prior quarter.
• The five-year high for Gross Profit was $74.9 million in Q4 2025, with the low at $15.8 million in Q1 2022.
• Historically, Gross Profit has averaged $41.8 million across 5 years, with a median of $40.1 million in 2023.
• Annual changes were most pronounced in 2022 — Gross Profit soared 271.1% — and 2024, when it advanced 1.39%.
• Xeris Biopharma Holdings' Gross Profit stood at $26.9 million in 2022, then surged by 37.12% to $36.8 million in 2023, then jumped by 37.48% to $50.6 million in 2024, then jumped by 47.88% to $74.9 million in 2025, then declined by 3.08% to $72.6 million in 2026.
• The last three Gross Profit figures came in at $72.6 million (Q1 2026), $74.9 million (Q4 2025), and $63.4 million (Q3 2025), per Business Quant data.